| Abstract | Title | Date/Time | Author |
| 6 | Plenary Scientific Session presentation | Brentuximab Vedotin plus doxorubicin, vinblastine, dacarbazine (A+AVD) as frontline therapy demonstrates superior modified progression-free survival versus ABVD in patients with previously untreated stage III or IV Hodgkin lymphoma (HL): the phase 3 ECHELON-1 study | Sunday, December 10, 2017: 2:00 PM-4:00 PM Bldg C, Lvl 1, Hall C2-C3 (Georgia World Congress Center) | Connors JM, Jurczak W, Straus DJ, Ansell SM, Kim WS, Gallamini A, Younes A, Aleksejev S, et al. |
 | |||
| 143 | Oral Presentation | Inotuzumab Ozogamicin in Combination with Bosutinib for Patients with Relapsed or Refractory Ph+ ALL or CML in Lymphoid Blast Phase | Saturday, December 9, 2017: 12:00 PM-1:30 PM Bldg C, Lvl 1, Hall C4 (Georgia World Congress Center) | Jain N, Cortes JE, Ravandi F, Konopleva M, Alvarado Y, Kadia T, Wierda WG, Borthakur G, et al. |
| |||
| 187 | Oral Presentation | Encouraging Early Results from the First in-Human Clinical Trial of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate, in Relapsed/Refractory B-Cell Lineage Non-Hodgkin Lymphoma | Saturday, December 9, 2017: 2:00 PM Bldg A, Lvl 4, A411-A412 (Georgia World Congress Center) | Kahl BS, Hamadan M, Caimi P, Carlo-Stella C, Reid E, Feingold J, Ardeshna KM, Radford J, et al. |
| |||
| 191 | Oral Presentation | Brentuximab Vedotin with R-CHP chemotherapy as frontline treatment for patients with CD30 positive primary mediastinal large B-cell, diffuse large B-cell, and grey zone lymphomas: results of a phase I/II multisite trial | Saturday, December 9, 2017: 3:00 PM Bldg A, Lvl 4, A411-A412 (Georgia World Congress Center) | Svoboda J, Landsburg DJ, Nasta SD, Barta SK, Khan N, Fung HC, Tan RC, Filicko-O’Hara J, et al. |
| |||
| 513 | Oral Presentation | A Phase I/II Study on the Anti-CD3/CD7 Immunotoxin Combination (T-Guard™) for the Treatment of Steroid-Refractory Acute Gvhd | Sunday, December 10, 2017: 5:00 PM Bldg B, Lvl 2, B211-B212 (Georgia World Congress Center) | Groth C, Groningen LFJ, Bremmers MEJ, Preijers FWMB, Dolstra H, Matos TR, Reicherts C, Van Hooren EG, et al. |
| |||
| 573 | Oral Presentation | High Frequency of CD74 Expression in B-Cell Non-Hodgkin’s Lymphoma (NHL) and Targeting with SΤRO-001, a Novel Anti-CD74 Antibody Drug Conjugate (ADC) with Potent In Vitro Cytotoxicty and In Vivo Anti-Tumor Activity | Monday, December 11, 2017: 7:30 AM Bldg B, Lvl 2, B213-B214 (Georgia World Congress Center) | Yu A, Abrahams C, Embry M, Li X, Zhao S, Henningsen R, DeAlmeida V, Matheny S, et al. |
| |||
| 649 | Oral Presentation | Results from a phase 1/2 study of Brentuximab Vedotin in combination with nivolumab in patients with relapsed or refractory Hodgkin lymphoma | Monday, December 11, 2017: 10:30 AM Bldg A, Lvl 4, Marcus Aud. (Georgia World Congress Center) | Herrera AF, Moskowitz AJ, Bartlett NL, Vose JM, Ramchandren R, Feldman TA, LaCasce AS, Ansell SM, et al. |
| |||
| 652 | Oral Presentation | Efficacy of Chemotherapy or Chemo-Anti-PD-1 Combination after Unsatisfactory Response of Anti-PD-1 Therapy for Relapsed and Refractory Hodgkin Lymphoma: A Retrospective Series from Lysa Centers | Monday, December 11, 2017: 11:15 AM Bldg A, Lvl 4, Marcus Aud. (Georgia World Congress Center) | Rossi C, Gilhodes J, Maerevoet M, Herbaux C, Brice P, Garciaz S, Borel C, Ysebaert L, et al. |
| |||
| 733 | Oral Presentation | Sequential Brentuximab Vedotin (BV) before and after Adriamycin, Vinblastine, and Dacarbazine (Bv-AVD) for Older Patients with Untreated Classical Hodgkin Lymphoma (cHL): Final Results from a Multicenter Phase II Study | Monday, December 11, 2017: 2:45 PM Bldg A, Lvl 4, Marcus Aud. (Georgia World Congress Center) | Evens AM, Advani RH, Fanale MA, Smith SM, Helenowski I, Jovanovic B, Bociek RG, Klein A, et al. |
| |||
| 734 | Oral Presentation | A Pilot Study of Brentuximab Vedotin and AVD Chemotherapy Followed By 20 Gy Involved-Site Radiotherapy in Early Stage, Unfavorable Risk Hodgkin Lymphoma | Monday, December 11, 2017: 3:00 PM Bldg A, Lvl 4, Marcus Aud. (Georgia World Congress Center) | Kumar A, Casulo C, Advani RH, Budde L, Barr PM, Batlevi CL, Caron P, Chen RW, et al. |
| |||
| 738 | Oral Presentation | Phase II Study of Brentuximab Vedotin Plus Ibrutinib for Patients with Relapsed/Refractory Hodgkin Lymphoma | Monday, December 11, 2017: 4:00 PM Bldg A, Lvl 4, Marcus Aud. (Georgia World Congress Center) | Chen RW, Palmer JM, Herrera AF, Armenian SH, Mei M, Popplewell L, Fueger A, Qasim I, et al. |
| |||
| 811 | Oral Presentation | Remissions of Acute Myeloid Leukemia and Blastic Plasmacytoid Dendritic Cell Neoplasm Following Treatment with CD123-Specific CAR T Cells: A First-in-Human Clinical Trial | Monday, December 11, 2017: 4:30 PM Bldg B, Lvl 5, Murphy BR 1-2 (Georgia World Congress Center) | Budde L, MD, Song JY, Kim Y, Blanchard S, Wagner J, Stein AS, Weng L, Del Real M, et al. |
| |||
| 1312 | Poster Presentation | IMGN779, a Next-Generation CD33-Targeting Antibody-Drug Conjugate (ADC) Demonstrates Initial Antileukemia Activity in Patients with Relapsed or Refractory Acute Myeloid Leukemia. | Saturday, December 9, 2017, 5:30 PM-7:30 PM Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center) | Cortes JE, Traer E, Wang ES, Erba HP, Blum W, Arana-Yi C, Sloss CM, et al. |
| |||
| 1321 | Poster Presentation | Interim Data from a Phase 1 Study Evaluating Pyrrolobenzodiazepine-Based Antibody Drug Conjugate ADCT-402 (Loncastuximab Tesirine) Targeting CD19 for Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia | Saturday, December 9, 2017, 5:30 PM-7:30 PM Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center) | Jain N, Klisovic RB, Stock W, Ungar D, Zeidan AM, Atallah E, McCloskey J, Heffner L, et al. |
| |||
| 1357 | Poster Presentation | IMGN779, a Next Generation CD33-Targeting ADC, Combines Effectively With Cytarabine in Acute Myeloid Leukemia (AML) Preclinical Models, Resulting in Increased DNA Damage Response, Cell Cycle Arrest and Apoptosis In Vitro, and Prolonged Survival In Vivo. | Saturday, December 9, 2017, 5:30 PM-7:30 PM Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center) | Adams S, Kelly M, McCarthy R, Wilhelm A, Watkins K, Lanieri L, Sloss CM, Romanelli A. |
| |||
| 1374 | Poster Presentation | An mTORC1/2 Kinase Inhibitor Remarkably Enhances the Cytotoxicity of Gemtuzumab Ozogamicin By Activating Lysosomal Function and Cell Cycle Promotion in AML Cells | Saturday, December 9, 2017, 5:30 PM-7:30 PM Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center) | Maimaitili Y, Inase A, Minami H, Matsuoka H. |
| |||
| 1378 | Poster Presentation | HMBD004, a Novel Anti-CD47xCD33 Bispecific Antibody Displays Potent Anti-Tumor Effects in Pre-Clinical Models of AML. | Saturday, December 9, 2017, 5:30 PM-7:30 PM Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center) | Boyd-Kirkup J , Thakkar D, Brauer P, Zhou J, Chng WJ, Ingram PJ. |
| |||
| 1495 | Poster Presentation | Safety and Preliminary Antitumor Activity of the Anti-PD-1 Monoclonal Antibody REGN2810 Alone or in Combination with REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients with B-Lymphoid Malignancies | Saturday, December 9, 2017, 5:30 PM-7:30 PM Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center) | Borchmann P, Wagner-Johnston ND, Provencio N, Cordoba R, Papadopoulos K, Martín A, Grande C, et al. |
| |||
| 1509 | Poster Presentation | Updated Analyses of the International, Open-Label, Randomized, Phase 3 Alcanza Study: Longer-Term Evidence for Superiority of Brentuximab Vedotin Versus Methotrexate or Bexarotene for CD30-Positive Cutaneous T-Cell Lymphoma (CTCL) | Saturday, December 9, 2017, 5:30 PM-7:30 PM Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center) | Horwitz SM, Scarisbrick JJ, Dummer R, Duvic M, Kim YH, Walewski J, Whittaker S, Quaglino P, et al. |
| |||
| 1510 | Poster Presentation | Interim Results from a Phase 1 Study of ADCT-301 (Camidanlumab Tesirine) Show Promising Activity of a Novel Pyrrolobenzodiazepine-Based Antibody Drug Conjugate in Relapsed/Refractory Hodgkin/Non-Hodgkin Lymphoma | Saturday, December 9, 2017, 5:30 PM-7:30 PM Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center) | Horwitz SM, Hamadani M, Fanale MA, Feingold J, AI Spira, Fields PA, Menne T, Karnad A, et al. |
| |||
| 1528 | Poster Presentation | A Pilot Study of Weekly Brentuximab Vedotin in Patients with CD30+ Malignancies Resistant to Every 3 Week Brentuximab Vedotin | Saturday, December 9, 2017, 5:30 PM-7:30 PM Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center) | Poston JN, Fromm JR, Rasmussen HA, Shustov AR, Libby III EN, Smith SD, Gooley T, Gopal AK. |
| |||
| 1540 | Poster Presentation | Polatuzumab Vedotin Alone or in Combination with Obinutuzumab Synergistically Enhances in-Vitro Cytotoxicity and Cytokine Release Against CD20+/ CD79b+ Burkitt Lymphoma (BL) /Primary Mediastinal Large B Cell Lymphoma (PMBL) | Saturday, December 9, 2017, 5:30 PM-7:30 PM Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center) | Tiwari A, Edani D, Ayello J, Klein C, Lee DA, Cairo MS. |
| |||
| 1894 | Poster Presentation | Non-Genotoxic Conditioning for Hematopoietic Stem Cell Transplant Using a Human Antibody Drug Conjugate Targeting C-KIT | Saturday, December 9, 2017, 5:30 PM-7:30 PM Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center) | Hartigan AJ, Pearse BR, McDonough SM, Proctor JL, , Adams HL, McShea MA, Hoban MD, et al |
| |||
| 2128 | Poster Presentation | Real World Clinical and Economic Burden of Patients with Hodgkin Lymphoma (HL) Who Fail Frontline (FL) Therapy in the US. | Saturday, December 9, 2017, 5:30 PM-7:30 PM Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center) | Straus DJ, Bonafede M, Feliciano J, Cai Q, Noxon V, Princic N, Josephson N, Richhariya A. |
| |||
| 2173 | Poster Presentation | Patient-Reported Distress in Hodgkin Lymphoma Patients on Active Therapy Vs. Long-Term Survivors | Saturday, December 9, 2017, 5:30 PM-7:30 PM Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center) | Troy JD, Locke SC, Pupa MR, Feliciano J, Richhariya A, LeBlanc TW. |
| |||
| 2526 | Poster Presentation | Drug Transporter ABCB1 SNP Predicts Outcome in Patients with Acute Myeloid Leukemia Treated with Gemtuzumab Ozagamicin: A Report from Children’s Oncology Group AAML0531 Trial | Sunday, December 10, 2017, 6:00 PM-8:00 PM Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center) | Chauhan L, Alonzo TA, Wang J, Loken MR, Pollard JA, Aplenc R, Raimondi SC, et al. |
| |||
| 2538 | Poster Presentation | Effect of Renal and/or Hepatic Impairment on the Pharmacokinetics and Safety of Inotuzumab Ozogamicin in Relapsed or Refractory B-Cell Acute Lymphoblastic Leukemia. | Sunday, December 10, 2017, 6:00 PM-8:00 PM Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center) | Garrett M, Kantarjian HK, DeAngelo DJ, Boni J. |
| |||
| 2543 | Poster Presentation | Elucidating Exposure-Response (Safety and Efficacy) of ADCT-402 (Loncastuximab Tesirine), a Novel Pyrrolobenzodiazepine-Containing Antibody Drug Conjugate, for Recommended Phase 2 Dose Determination in Patients with Relapsed or Refractory Non-Hodgkin Lymphoma | Sunday, December 10, 2017, 6:00 PM-8:00 PM Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center) | O’Connor OA, Kahl BS, Mehdi Hamadani, Caimi P, Reid E, Feingold J, Havenith K, et al. |
| |||
| 2576 | Poster Presentation | A Phase I/II Study of Inotuzumab Ozogamicin in Combination with Low-Intensity Chemotherapy (mini-hyper-CVD) for Older Patients with Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia | Sunday, December 10, 2017, 6:00 PM-8:00 PM Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center) | Short NJ, Kantarjian HM, Ravandi F, Huang X, Jain N, Daver N, Thomas DA, Pemmaraju N, Khouri R, et al. |
| |||
| 2597 | Poster Presentation | Updated Results of the Phase II Trial of Inotuzumab Ozogamicin (INO) Combined with Mini-Hyper-CVD As Salvage Therapy for Relapsed/Refractory (R/R) B-Cell Acute Lymphoblastic Leukemia (B-ALL) | Sunday, December 10, 2017, 6:00 PM-8:00 PM Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center) | Assi R, Kantarjian HM, Khouri R, Ravandi F, Kebriaei P, Short NJ, Thomas DA, Garcia-Manero G, et al. |
| |||
| 2598 | Poster Presentation | Safety and Efficacy of Blinatumomab in Combination with a Tyrosine Kinase Inhibitor for the Treatment of Relapsed Philadelphia Chromosome-Positive Leukemia | Sunday, December 10, 2017, 6:00 PM-8:00 PM Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center) | Assi R, Kantarjian HM, Short NJ, Daver N, Takahashi K, Garcia-Manero G, DiNardo CD, Khouri M, et al. |
| |||
| 2619 | Poster Presentation | Prolonged Azacitidine Exposure Alters Immunophenotype in Myeloid Leukemia Cell Lines | Sunday, December 10, 2017, 6:00 PM-8:00 PM Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center) | Kaeding A, Pardo L, Loken MR, Brodersen LE, Tarlock K, Meshinchi S. |
| |||
| 2639 | Poster Presentation | Bispecific Anti-CD123 x Anti-CD3 Adaptir™ Molecules APVO436 and APVO437 Have Broad Activity Against Primary Human AML Cells In Vitro | Sunday, December 10, 2017, 6:00 PM-8:00 PM Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center) | Godwin CD, Bates OM, Laszlo GS, Gottschalk R Comeau MR, Hoyos GH, Walter RB. |
| |||
| 2641 | Poster Presentation | Mesothelin Is a Novel Disease Marker and Potential Therapeutic Target in Pediatric Acute Myeloid Leukemia | Sunday, December 10, 2017, 6:00 PM-8:00 PM Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center) | Kaeding A, MD1,2, Katherine Tarlock, MD1,2, Sonali Barwe, PhD, MSc3*, Anilkumar Gopalakrisnapillai, PhD4*, Todd A Alonzo, PhD5*, Robert B Gerbing6*, Michael R. Loken, PhD7*, Rhonda E. Ries, MA8*, |
| |||
| 2661 | Poster Presentation | CD33 DE2 Transcript Variant Encoded By Splicing Polymorphism Is Devoid of Antibody Binding Site and Lacks Response to CD33 Directed Antibody Drug Conjugates | Sunday, December 10, 2017, 6:00 PM-8:00 PM Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center) | Tarlock K, Lamba J, Meshinchi S. |
| |||
| 2662 | Poster Presentation | Results from an Ongoing Phase 1 Study Indicate ADCT-301 (Camidanlumab Tesirine) Is Well-Tolerated in Patients with Relapsed or Refractory CD25-Positive Acute Leukemia | Sunday, December 10, 2017, 6:00 PM-8:00 PM Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center) | Goldberg AD, Tallman MS, Solh, MM, Ungar D, Rizzieri DA, Walter RB, Spira AI, Chung KY, Stock W, et al. |
| |||
| 2718 | Poster Presentation | CD123 Expression Patterns and Potential of IMGN632, a CD123-Targeted Antibody Drug Conjugate, in Acute Lymphoblastic Leukemia. | Sunday, December 10, 2017, 6:00 PM-8:00 PM Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center) | Angelova E, Audette C, Kovtun Y, Daver N, Wang SA, Pierce S, Konoplev SN, et al. |
| |||
| 2790 | Poster Presentation | Five-year survival results: frontline Brentuximab Vedotin in combination with CHP in patients with CD30-expressing Peripheral T-cell Lymphomas | Sunday, December 10, 2017, 6:00 PM-8:00 PM Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center) | Fanale MA, Horwitz SM, Forero-Torres A, Bartlett NL, Advani RH, Pro B, Chen RW, Davies A, et al. |
| |||
| 2798 | Poster Presentation | Changes in serum TARC predict PET response among pediatric patients with relapsed or refractory Hodgkin lymphoma treated with Brentuximab Vedotin and gemcitabine: a report from the Children’s Oncology Group | Sunday, December 10, 2017, 6:00 PM-8:00 PM Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center) | Cole PD, Spira M, McCarten KM, Horton TM, Pei Q, Metzger M, Drachtman RA, Kelly KM. |
| |||
| 2802 | Poster Presentation | High-Dose Bendamustine Plus Brentuximab Combination Is Effective and Has a Favourable Toxicity Profile in the Treatment of Refractory and Relapsed Hodgkin Lymphoma | Sunday, December 10, 2017, 6:00 PM-8:00 PM Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center) | Cerichione C, Di Perna M, Pugliese N, Della Pepa R, Pane F, Picardi M. |
| |||
| 2806 | Poster Presentation | Radiographic and high-throughput sequencing (HTS)-based response assessment after Brentuximab Vedotin plus ifosfamide, carboplatin, and etoposide (ICE) for relapsed/refractory classical Hodgkin Lymphoma: Updated results of a Phase I/II trial | Sunday, December 10, 2017, 6:00 PM-8:00 PM Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center) | Cassaday RD, Fromm JR, Cowan AJ, Smith SD, Libby III EN, Philip M, Nartea ME, et al. |
| |||
| 2909 | Poster Presentation | Phase 2 Study of Brentuximab Vedotin in Patients with Advanced Systemic Mastocytosis | Sunday, December 10, 2017, 6:00 PM-8:00 PM Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center) | Baird JH, Verstovsek S, George TI, Reyes I Abuel J, Perkins C, Langford C, Schroeder K, Gotlib J. |
| |||
| 3017 | Poster Presentation | Evaluation of ROR1 Targeted Antibody Drug Conjugates in Acute and Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma | Sunday, December 10, 2017, 6:00 PM-8:00 PM Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center) | Hu E, Do P, Mani R, Frissora F, Peng H, Waldmeier L, Beerli R, et al. |
| |||
| 3070 | Poster Presentation | Preclinical Evaluation of Hdp-101, a Novel Anti-Bcma Antibody-Drug Conjugate, in Multiple Myeloma | Sunday, December 10, 2017, 6:00 PM-8:00 PM Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center) | Ko J, Brewing C, Figueroa V, Lehners N, Baumann A, Pálfi A, Müller C, et al. |
| |||
| 3153 | Poster Presentation | Preclinical Evaluation of MEDI2228, a BCMA-Targeting Pyrrolobenzodiazepine-Linked Antibody Drug Conjugate for the Treatment of Multiple Myeloma | Sunday, December 10, 2017, 6:00 PM-8:00 PM Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center) | Kinder K, Meekin J, Varkey R, Xiao X, Zhong H, Breen S, Hurt E, et al. |
| |||
| 3826 | Poster Presentation | CD33–Single Nucleotide Polymorphism (CD33-SNP) Score Predicts Gemtuzumab Ozogamicin Response in Childhood Acute Myeloid Leukemia: Report from Children’s Oncology Group AAML0531 Trial | Monday, December 11, 2017, 6:00 PM-8:00 PM Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center) | Lamba J, Chauhan L, Shin M, Loken MR, Pollard JA, Wang J, Aplenc R, et al. |
| |||
| 4077 | Poster Presentation | A Phase II Study of Brentuximab Vedotin for Relapsed or Refractory CD30-Positive Non-Hodgkin Lymphomas Other Than Anaplastic Large Cell Lymphoma | Monday, December 11, 2017, 6:00 PM-8:00 PM Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center) | Park S, Kim SJ, Hong JY, Yoon DH, Kim JS, Kang HJ, Eom HS, MH Lee, et al. |
| |||
| 4078 | Poster Presentation | Increased Rate of Pulmonary Toxicity in Pediatric Patients with Relapsed Hodgkin Lymphoma Receiving Brentuximab Vedotin | Monday, December 11, 2017, 6:00 PM-8:00 PM Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center) | Faulk KE, Sopfe J, Pyle L, Liptzin DR, Liu AK, Franklin ARK, Cost CR. |
| |||
| 4082 | Poster Presentation | Patient and Physician Preferences for Front-Line Treatment of Advanced Stage Hodgkin Lymphoma in Germany, France and the United Kingdom | Monday, December 11, 2017, 6:00 PM-8:00 PM Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center) | Broeckelmann P, Stamatoullas A, McMullen S, Wilson B, Mueller K, Goring S, Zagadailov E, et al. |
| |||
| 4090 | Poster Presentation | Brentuximab Vedotin in Combination with Bendamustine in Relapsed or Refractory Hodgkin Lymphoma: A Retrospective Analysis on 23 Paediatric Patients or Young Adults | Monday, December 11, 2017, 6:00 PM-8:00 PM Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center) | Vinti L, Locatelli F, Merli P, Parasole R, Buffardi S, Pillon M, Strocchio L, Girardi K. |
| |||
| 4105 | Poster Presentation | TRPH-222, a Novel Anti-CD22 Antibody Drug Conjugate (ADC), Has Signficant Anti-Tumor Activity in NHL Xenografts and Is Well Tolerated in Non-Human Primates | Monday, December 11, 2017, 6:00 PM-8:00 PM Bldg A, Lvl 1, Hall A2 (Georgia World Congress Center) | Maclaren A, Levin N, Lowman H, Trikha M. |
|
Home ASH 2017: Oral Presentations and Posters